BRIEF-TDS Board Announces Unanimous Support For Sale Of Uscellular's Wireless Operations And Select Spectrum Assets To T-Mobile-February 2024-www.financetom.com

BRIEF-TDS Board Announces Unanimous Support For Sale Of Uscellular's Wireless Operations And Select Spectrum Assets To T-Mobile

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-TDS Board Announces Unanimous Support For Sale Of Uscellular's Wireless Operations And Select Spectrum Assets To T-Mobile

May 28, 2024 5:26 AM

May 28 (Reuters) - Telephone and Data Systems Inc ( TDS/PV )

* TDS BOARD ANNOUNCES UNANIMOUS SUPPORT FOR SALE OF

USCELLULAR'S

WIRELESS OPERATIONS AND SELECT SPECTRUM ASSETS TO T-MOBILE

Source text for Eikon:

Further company coverage:

Previous page： BRIEF-Fusion Pharmaceuticals To Be Acquired By Astrazeneca, Accelerating Development Of Next-Generation Radioconjugates To Treat Cancer Next page： AstraZeneca to buy Fusion Pharma for $2 billion in cash

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

BRIEF-Fusion Pharmaceuticals To Be Acquired By Astrazeneca, Accelerating Development Of Next-Generation Radioconjugates To Treat Cancer

Mar 19, 2024

March 19 (Reuters) - Fusion Pharmaceuticals Inc ( FUSN ) : * FUSION PHARMACEUTICALS TO BE ACQUIRED BY ASTRAZENECA, ACCELERATING DEVELOPMENT OF NEXT-GENERATION RADIOCONJUGATES TO TREAT CANCER * REPRESENTING A TOTAL TRANSACTION VALUE OF APPROXIMATELY $2.4 BILLION INCLUDING CVR * SHAREHOLDERS TO RECEIVE $21.00 PER SHARE IN CASH AT CLOSING PLUS A NON-TRANSFERRABLE CVR OF $3.00 PER SHARE * UPFRONT...

AstraZeneca to buy Fusion Pharma for $2 billion in cash

Mar 19, 2024

March 19 (Reuters) - AstraZeneca ( AZN ) said on Tuesday it has agreed to buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc ( FUSN ) for about $2 billion in cash. The drugmaker will pay $21 per Fusion share plus a non-transferable contingent value right of $3 per share. ...

Thyssenkrupp starts due diligence phase on marine unit deal with Carlyle

Mar 19, 2024

March 19 (Reuters) - Thyssenkrupp on Tuesday said it has entered a due diligence phase on the sale of its marine unit with investment firm Carlyle. At the same time, talks are being held with the German government on the state's participation in thyssenkrupp's marine business, the industrial conglomerate added. ...

Australia's Boral urges shareholders to reject Seven Group's $1.3 billion offer

Mar 19, 2024

(Reuters) -Australia's Boral on Tuesday recommended investors reject its largest shareholder Seven Group Holdings' A$1.9 billion ($1.25 billion) offer for the company claiming it undervalues the building products group. Seven Group, controlled by billionaire Kerry Stokes and his family, already owns nearly 72% of Boral and had launched a bid last month to acquire full control of Boral. The proposal...